UPDATE: Geron (GERN) PT Cut to $5 at Piper Jaffray Following 'Mixed' Imetelstat Message
- Stocks gear up for Big Tech earnings; yen toys with danger zone
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises on robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
BTIG Maintains 'Neutral' Rating on Geron (GERN) Following Imetelstat Update
September 13, 2016 6:39 AM EDTBTIG affirms Geron Corp. (Nasdaq: GERN) with a Neutral rating following an update on the ongoing imetelstat Phase II IMbark trial in MF and Phase II/III trial in MDS.
Analyst Ling Wang noted the following key points late Monday:
Imetelstat showed consistent safety profile in both trials. Safety profile of... MoreBTIG Reaffirms Geron (GERN) at 'Neutral' Following Imetelstat Update
September 12, 2016 11:13 AM EDTBTIG affirms Geron Corp. (Nasdaq: GERN) with a Neutral rating after the company provided updates on the clinical trials being conducted by Janssen Research & Development, LLC, of the... More
Geron Corp (GERN) Notes Janssen Imetelstat Trials Continuing
September 12, 2016 7:32 AM EDTGeron Corporation (Nasdaq: GERN) today provided updates on the clinical trials being conducted by Janssen Research & Development, LLC, of the telomerase inhibitor imetelstat. Planned internal reviews of initial data from both trials have been completed by Janssen, and both trials are continuing in order to evaluate additional and more mature data.
IMbarkTM
IMbarkTM (NCT02426086) was originally designed as a Phase 2 clinical trial to evaluate two dose levels of imetelstat (either 4.7 mg/kg or 9.4 mg/kg administered every three weeks) in approximately 200 patients (approximately 100 patients per dosing arm) with Intermediate-2 or... More